WallStSmart

Alcon AG (ALC)vsBioLife Solutions Inc (BLFS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 10360% more annual revenue ($10.63B vs $101.66M). ALC leads profitability with a 7.7% profit margin vs -2.9%. ALC appears more attractively valued with a PEG of 1.54. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

BLFS

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 3.7Quality: 9.0
Piotroski: 4/9Altman Z: 5.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-24.8%)

Margin of Safety

-24.8%

Fair Value

$63.62

Current Price

$70.26

$6.64 premium

UndervaluedFair: $63.62Overvalued
BLFSOvervalued (-9.0%)

Margin of Safety

-9.0%

Fair Value

$20.42

Current Price

$29.15

$8.73 premium

UndervaluedFair: $20.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

BLFS3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.9610/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
24.7%8/10

Revenue surging 24.7% year-over-year

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BLFS4 concerns · Avg: 2.5/10
Market CapQuality
$1.36B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.1%3/10

Operating margin of 0.1%

PEG RatioValuation
15.092/10

Expensive relative to growth rate

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : BLFS

The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 41.1x leaves little room for execution misses.

Bear Case : BLFS

The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.

Key Dynamics to Monitor

ALC profiles as a value stock while BLFS is a growth play — different risk/reward profiles.

BLFS carries more volatility with a beta of 1.94 — expect wider price swings.

BLFS is growing revenue faster at 24.7% — sustainability is the question.

ALC generates stronger free cash flow (274M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

BioLife Solutions Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.

Want to dig deeper into these stocks?